Results 291 to 300 of about 125,713 (396)

Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders

Phytotherapy Research, EarlyView.
ABSTRACT Deregulation of the mechanistic target of the rapamycin (mTOR) pathway plays an important role in cancer genesis and progression, making it an attractive target for cancer treatment. Disrupting the mTOR pathway contributes to uncontrolled cell growth, increased proliferation, and enhanced cell survival, all of which are hallmarks of cancer ...
Sonali Khanal, Manjusha Pillai, Md. Shimul Bhuia, Muhammad Torequl Islam, Onkar Sharma, Rachna Verma, Eugenie Nepovimova, Kamil Kuca, Dinesh Kumar, Raihan Chowdhury   +9 more
wiley   +1 more source

Extramedullary chronic phase chronic myeloid leukaemia (CML) involving the central nervous system: A case report. [PDF]

EJHaem
Deshpande A, Osman D, Murthy V, Hussein H.   +3 more
europepmc   +1 more source

Malignancies and immunoglobulin G4‐related disease

Rheumatology &Autoimmunity, EarlyView.
Immunoglobulin G4‐related disease (IgG4‐RD) is associated with increased cancer risk. Malignancies affect both IgG4‐RD involved organs, such as the lung, pancreas, bile duct, and prostate, and noninvolved organs, such as the gastrointestinal duct. B‐cell neoplasms constitute a proportion of the malignancies linked to this disease.
Jingna Li, Wen Zhang
wiley   +1 more source

Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential. [PDF]

J Cell Mol Med
Huang J, Xiao J, He L, Dai W, Xiao J, Li Y, He Y, Yu L.   +7 more
europepmc   +1 more source

Plasmonic Mesoporous Gold‐Based SERS Biosensor for Ovarian Cancer‐Derived Extracellular Vesicles

Small, EarlyView.
The nanoengineered mesoporous gold (mAu)‐based SERS platform enables rapid, sensitive detection of PLAP‐positive extracellular vesicles (EVs) in ovarian cancer (OC), with detection limits as low as 100 EVs mL−1. Achieving over 80% sensitivity and 98% specificity in clinical samples, this cost‐effective, non‐invasive tool shows promise for early cancer ...
Javeria Bashir, Mostafa Kamal Masud, Asep Sugih Nugraha, Chia‐Hung Liu, Arya Vasanth, Aditya Ashok, S M Azad Hossain, Emtiaz Ahmed, Tanja Pejovic, Terry Morgan, John Hooper, Andrew Lai, Dominic Guanzon, Yusuf Valentino Kaneti, Md Shahriar A. Hossain, Carlos Salomon, Yusuke Yamauchi   +16 more
wiley   +1 more source

Radotinib-induced Eruptive Melanocytic Naevi in a Patient with Chronic Myeloid Leukaemia.

Indian J Dermatol
Lee JM, Han B, Lee JH, Han TY, Choi JE.
europepmc   +1 more source

Chronic myeloid leukaemia: A therapeutic challenge

Annals of Oncology, 1995
John M. Goldman, Tariq I. Mughal
openaire   +3 more sources

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

VIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma, Junxin Chen, Yuan Du, Zhihao Cao, Weizhi Ji, Yuyu Niu, Zebin Yang   +6 more
wiley   +1 more source